We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pacific Biosciences (PACB) Beats on Q2 Earnings & Revenues
Read MoreHide Full Article
Pacific Biosciences of California, Inc. (PACB - Free Report) incurred second-quarter 2019 adjusted loss of 16 cents per share, narrower than the Zacks Consensus Estimate of a loss of 18 cents. The company had incurred a loss of 17 cents in the year-ago quarter.
Revenues totaled $24.6 million, which beat the Zacks Consensus Estimate of $22 million and improved 14.1% from the year-ago quarter’s tally.
Segmental Analysis
Product Revenue: At this segment, revenues amounted to $21.3 million, up 15% from the prior-year quarter’s tally.
Service and Other Revenue: At this segment, revenues came in at $3.4 million, up 9% year over year.
Pacific Biosciences of California, Inc. Price, Consensus and EPS Surprise
Gross profit in the second quarter of 2019 was $9.6 million, up 8.5% on a year-over-year basis. Gross margin was 39% of total revenues, contracting 210 bps from the year-ago quarter.
Research and Development expenses fell 4.8% to $14.9 million in the quarter. Further, sales, general and administrative expenses increased 27.7% to $19.1 million.
Operating expenses totaled $33.9 million, up 11.1% year over year.
About the Illumina & Pacific Biosciences Merger
Illumina (ILMN) has confirmed its merger with Pacific Biosciences. Per management, the total value of the deal is approximately $1.2 billion. The agreement is expected to close by mid-2019.
For the three months ended June 30, 2019, the company realized around $3.8 million in operating expenses associated with the merger.
Zacks Rank
Pacific Biosciences carries a Zacks Rank #3 (Hold).
Stryker delivered second-quarter 2019 adjusted earnings per share of $1.98, beating the Zacks Consensus Estimate by 2.6%. Revenues of $3.65 billion surpassed the Zacks Consensus Estimate by 1.4%.
Baxter delivered second-quarter 2019 adjusted earnings of 89 cents per share, which surpassed the Zacks Consensus Estimate of 81 cents by 9.9%. Revenues of $2.84 billion outpaced the Zacks Consensus Estimate of $2.79 billion by 1.9%.
Intuitive Surgical reported second-quarter 2019 adjusted earnings per share of $3.25, which beat the Zacks Consensus Estimate of $2.85. Revenues were $1.1 billion, outpacing the Zacks Consensus Estimate of $1.03 billion.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
Pacific Biosciences (PACB) Beats on Q2 Earnings & Revenues
Pacific Biosciences of California, Inc. (PACB - Free Report) incurred second-quarter 2019 adjusted loss of 16 cents per share, narrower than the Zacks Consensus Estimate of a loss of 18 cents. The company had incurred a loss of 17 cents in the year-ago quarter.
Revenues totaled $24.6 million, which beat the Zacks Consensus Estimate of $22 million and improved 14.1% from the year-ago quarter’s tally.
Segmental Analysis
Product Revenue: At this segment, revenues amounted to $21.3 million, up 15% from the prior-year quarter’s tally.
Service and Other Revenue: At this segment, revenues came in at $3.4 million, up 9% year over year.
Pacific Biosciences of California, Inc. Price, Consensus and EPS Surprise
Pacific Biosciences of California, Inc. price-consensus-eps-surprise-chart | Pacific Biosciences of California, Inc. Quote
Margin Analysis
Gross profit in the second quarter of 2019 was $9.6 million, up 8.5% on a year-over-year basis. Gross margin was 39% of total revenues, contracting 210 bps from the year-ago quarter.
Research and Development expenses fell 4.8% to $14.9 million in the quarter. Further, sales, general and administrative expenses increased 27.7% to $19.1 million.
Operating expenses totaled $33.9 million, up 11.1% year over year.
About the Illumina & Pacific Biosciences Merger
Illumina (ILMN) has confirmed its merger with Pacific Biosciences. Per management, the total value of the deal is approximately $1.2 billion. The agreement is expected to close by mid-2019.
For the three months ended June 30, 2019, the company realized around $3.8 million in operating expenses associated with the merger.
Zacks Rank
Pacific Biosciences carries a Zacks Rank #3 (Hold).
Earnings of MedTech Majors at a Glance
Some better-ranked stocks which reported solid results this earning season are Stryker Corporation (SYK - Free Report) , Baxter International Inc. (BAX - Free Report) and Intuitive Surgical, Inc. (ISRG - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Stryker delivered second-quarter 2019 adjusted earnings per share of $1.98, beating the Zacks Consensus Estimate by 2.6%. Revenues of $3.65 billion surpassed the Zacks Consensus Estimate by 1.4%.
Baxter delivered second-quarter 2019 adjusted earnings of 89 cents per share, which surpassed the Zacks Consensus Estimate of 81 cents by 9.9%. Revenues of $2.84 billion outpaced the Zacks Consensus Estimate of $2.79 billion by 1.9%.
Intuitive Surgical reported second-quarter 2019 adjusted earnings per share of $3.25, which beat the Zacks Consensus Estimate of $2.85. Revenues were $1.1 billion, outpacing the Zacks Consensus Estimate of $1.03 billion.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>